News
PSTV
1.170
-7.87%
-0.100
Weekly Report: what happened at PSTV last week (1209-1213)?
Weekly Report · 17h ago
Weekly Report: what happened at PSTV last week (1202-1206)?
Weekly Report · 12/09 09:54
Plus Therapeutics Price Target Cut to $19.00/Share From $20.00 by Ascendiant Capital
Dow Jones · 12/09 09:49
Plus Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 12/09 09:49
Ascendiant Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $19
Benzinga · 12/09 09:39
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Barchart · 12/04 06:30
Plus Therapeutics, Inc. Renews Master Services Agreement with Telix IsoTherapeutics to Secure Supply of Radiotherapeutic Isotope Re-186
Barchart · 12/03 16:48
Plus Therapeutics Announces Renewal Of Master Services Agreement With Telix
NASDAQ · 12/03 13:31
Plus Therapeutics expands strategic agreement with Telix IsoTherapeutics
TipRanks · 12/03 12:40
PLUS THERAPEUTICS EXPANDS STRATEGIC AGREEMENT WITH TELIX ISOTHERAPEUTICS GROUP FOR RHENIUM-186 RADIOISOTOPE SUPPLY
Reuters · 12/03 12:30
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Barchart · 12/03 06:30
Weekly Report: what happened at PSTV last week (1125-1129)?
Weekly Report · 12/02 09:54
Plus Therapeutics Price Target Announced at $8.00/Share by HC Wainwright & Co.
Dow Jones · 11/26 11:36
HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Announces $8 Price Target
Benzinga · 11/26 11:27
Promising Clinical Outcomes and Diagnostic Innovations Drive Buy Rating for Plus Therapeutics
TipRanks · 11/26 11:26
Plus Therapeutics Reports Promising Phase 1 Trial Results of Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases, Secures FDA Approval for Expanded Studies
Barchart · 11/25 16:48
Plus Therapeutics presents updated progress from its ReSPECT-LM Phase 1 trial
TipRanks · 11/25 12:45
Weekly Report: what happened at PSTV last week (1118-1122)?
Weekly Report · 11/25 09:50
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
Barchart · 11/25 06:30
Plus Therapeutics to present FORESEE clinical trial summary
TipRanks · 11/22 12:35
More
Webull provides a variety of real-time PSTV stock news. You can receive the latest news about Plus Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.